Influence of hypoxia‑related genetic polymorphisms on the prognosis of patients with metastatic gastric cancer treated with EOF

  • Authors:
    • Wenbo Tang
    • Xin Liu
    • Lixin Qiu
    • Xiaoying Zhao
    • Mingzhu Huang
    • Jiliang Yin
    • Jin Li
    • Weijian Guo
    • Xiaodong Zhu
    • Zhiyu Chen
  • View Affiliations

  • Published online on: November 15, 2017     https://doi.org/10.3892/ol.2017.7414
  • Pages:1334-1342
Metrics: HTML 0 views | PDF 0 views
0

Abstract

Tumor hypoxia is common in a number of solid tumor types including gastric cancer, and is associated with treatment resistance and poor prognosis. The present study aimed to investigate the function of hypoxia‑associated genetic polymorphisms in predicting treatment response and survival in patients with metastatic gastric cancer (MGC) treated with EOF (oxaliplatin and 5‑fluorouracil combined with epirubicin) as first‑line chemotherapy. The present retrospective study enrolled 108 Chinese patients with MGC receiving EOF as first‑line chemotherapy, and genotyped six single nucleotide polymorphisms (SNPs) in four hypoxia‑associated genes [myoglobin (MB) rs7292 and rs7293, ATP Binding Cassette Subfamily G Member 2 rs2231142, MutL homolog 1 (MLH1) rs1800734 and rs9852810, and Poly(ADP‑Ribose) Polymerase 1 rs1136410]. The results of the present study indicated that the CT/TT genotype of MB rs7292, as well as the GG genotype of MLH1 rs9852810, were independent favorable predictive factors of progression‑free survival [PFS; MB rs7292: hazard ratio (HR)=0.135, 95% confidence interval (CI)=0.057‑0.321, P<0.001; MLH1 rs9852810: HR=0.494, 95% CI=0.267‑0.913, P=0.024). Using a prognostic index based on the favorable SNPs for PFS (MB rs7292 CT/TT genotype, and MLH1 rs9852810 GG genotype), patients were classified into a low‑risk group (involving one or two of the two SNPs) and a high‑risk group (involving neither of the two SNPs), with a PFS of 180.0 and 117.0 days, respectively (P=0.002). The results of the present study demonstrated that the CT/TT genotype of MB rs7292 and the GG genotype of MLH1 rs9852810 were independent favorable predictive factors of PFS in patients with MGC treated with EOF. Identification of those SNPs in blood samples may allow for the prediction of the short‑term efficacy of first‑line EOF treatment in patients with MGC.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Tang, W., Liu, X., Qiu, L., Zhao, X., Huang, M., Yin, J. ... Chen, Z. (2018). Influence of hypoxia‑related genetic polymorphisms on the prognosis of patients with metastatic gastric cancer treated with EOF. Oncology Letters, 15, 1334-1342. https://doi.org/10.3892/ol.2017.7414
MLA
Tang, W., Liu, X., Qiu, L., Zhao, X., Huang, M., Yin, J., Li, J., Guo, W., Zhu, X., Chen, Z."Influence of hypoxia‑related genetic polymorphisms on the prognosis of patients with metastatic gastric cancer treated with EOF". Oncology Letters 15.1 (2018): 1334-1342.
Chicago
Tang, W., Liu, X., Qiu, L., Zhao, X., Huang, M., Yin, J., Li, J., Guo, W., Zhu, X., Chen, Z."Influence of hypoxia‑related genetic polymorphisms on the prognosis of patients with metastatic gastric cancer treated with EOF". Oncology Letters 15, no. 1 (2018): 1334-1342. https://doi.org/10.3892/ol.2017.7414